PHARMACEUTICAL SCIENCE BRINGS GENETICS AND IMMUNOLOGY TOGETHER TO EVOLVE A NEW DIMENSION IN TREATING CHILDHOOD CANCER: A REVIEWAbstract
Surgery, chemotherapy and radiation therapy has been the cornerstone of cancer management for decades. Since a decade or so, targeted therapies by way of Imatinib and Trastuzumab arrived that specifically target cancer cells and reply on specific molecular changes to identify them. These are in fact the standard treatment at present in several forms of cancer. But now in recent times, the fifth pillar of cancer treatment has gradually emerged where the patient’s immune system is hired to address and kill his own cancer cells. One such strategy for treatment is involving engineered immune cells of a patient to identify and kill his own tumours. Although this approach, often called adoptive cell transfer or ACT is now limited to small tests and trials, these are seen are true silver bullets in the days to come in treating cancer. This review discuss this new development in pharmaceutical science were living drugs are emerging through high end genetic engineering that exploit the specificity of an antibody and the unique cytotoxic effect of T cells to address cancer.
A. S. Singh* and M. Y. Tilawat
SVKM’S Narsee Monjee Institute of Management Studies, Babulde, Bank of Tapi River, Mumbai-Agra Road, Shirpur, Maharashtra, India
20 October, 2016
02 April, 2017
07 May, 2017
01 June, 2017